PORT WASHINGTON, N.Y., Nov. 2, 2012 (GLOBE NEWSWIRE) -- ACETO Corporation (Nasdaq:ACET), a global leader in the marketing, sale and distribution of products for Human Health, Pharmaceutical Intermediates and Performance Chemicals, today announced that Rising Pharmaceuticals Inc., its finished dosage form generics subsidiary, has signed a definitive agreement to market an authorized generic of the 10mg strength of Tranylcypromine Sulfate Tablets, an FDA approved authorized generic version of Covis Pharma’s Parnate® product. According to IMS Health data, U.S. market sales for Tranylcypromine Sulfate Tablets, which is used for the treatment of depression, were approximately $8 million for the twelve months ended June 2012.
